Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

RIMSA

- PMLiVE

FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined

Nearly 500,000 died from an opioid overdose between 1999 and 2019

- PMLiVE

Teva reaches $925,000 settlement to resolve drug price-fixing claims

Last year, the US Department of Justice charged Teva for conspiring with competitors in a generic drug price-fixing probe

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

- PMLiVE

US charges Teva for generic drug price-fixing plot

Company maintains it has not committed any wrongdoing

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

AbbVie says Allergan takeover delayed by FTC verdict

Merger now likely to complete in second quarter rather than first

- PMLiVE

AbbVie/Allergan merger faces renewed public opposition despite divestments

Consumer groups and public interest organisations raise new concerns

- PMLiVE

Teva’s weak pipeline hit by Tourette’s drug trial failure

Drug wasn't able to improve on placebo

- PMLiVE

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links